EUVIMEDEUVIMED entdecken
Crossref

Modern Low-Density Lipoprotein Cholesterol Formulas Outperform Direct Methods in Patients with Hypertriglyceridemia and Low Levels of Low-Density Lipoprotein Cholesterol

Jeffrey W Meeusen, Xin Yi iD, Steven W Cotten, Jacob B Nielsen, Leslie J Donato iD, Patricia M Jones iD, Alagar R Muthukumar, Rafael Zubirán iD, Alan T Remaley, Jing Cao iD

Clinical Chemistry · 04.11.2025 · 71 (11) · 1138-1146

DOI: 10.1093/clinchem/hvaf099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 03.09.2025. Verfasst von Jeffrey W Meeusen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Cholesterol, LDL. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Intramural Research Program of the National Heart, Lung, and Blood Institute, NIH HHS, Leducq Foundation for Cardiovascular Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Direct measurement of low-density lipoprotein cholesterol (LDL-C) is widely used and recommended by professional society guidelines despite its potential limitations in patients with hypertriglyceridemia and low LDL-C. This study evaluated the performance of 3 direct LDL-C (LDL-CD) assays, 2 modern LDL-C calculation methods [LDL-C Martin (LDL-CM), LDL-C modified Sampson (LDL-CS)] and the conventional Friedewald (LDL-CF) method against the reference method, beta-quantification (LDL-CBQ).

Methods

A total of 181 remnant sera from patients with standard lipid panel orders or from patients with LDL-CBQ orders with triglycerides (TG) ≥ 400 mg/dL (4.5 mmol/L), or with TG ≥ 150 mg/dL (1.69 mmol/L) and LDL-C < 70 mg/dL (1.8 mmol/L) were included. LDL-CD and lipid panel data were gathered from Abbott Alinity, Roche Cobas, and Siemens Atellica platforms.

Results

LDL-CD among the 3 platforms showed a median CV of 11.2%. In patients with TG <400 mg/dL, LDL-CM and LDL-CS demonstrated less bias and less misclassification at the clinical decision LDL-C levels than LDL-CF or LDL-CD. In the 400 to 800 mg/dL (9.0 mmol/L) TG group, LDL-CS was superior to LDL-CD or LDL-CM in accuracy. When TG is ≥ 800 mg/dL, LDL-CD (Roche) showed substantial bias from LDL-CBQ while LDL-CS (Roche) showed smaller but significant bias.

Conclusions

In summary, LDL-CD or LDL-CF showed little advantage over the 2 modern LDL-C calculation methods. LDL-CS showed the best overall correlation with LDL-CBQ and therefore is recommended to replace LDL-CF and potentially LDL-CD when making clinical decisions in patients with low LDL-C and hypertriglyceridemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertriglyceridemiaCholesterol, LDLHumansFemaleMaleMiddle AgedTriglyceridesAgedAdult

Substanzen

Cholesterol, LDLTriglycerides

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
  • Department of Clinical Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, United States.
  • Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
  • Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
  • Children's Health, Dallas, TX, United States.
  • Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States.

ORCID-Profile: Xin Yi, Leslie J Donato, Patricia M Jones, Rafael Zubirán, Jing Cao

Förderung

  • Intramural Research Program of the National Heart, Lung, and Blood Institute
  • NIH HHS
  • Leducq Foundation for Cardiovascular Research
  • Department of Pathology at the University of Texas Southwestern Medical Center
  • National Institutes of Health

Zitieren

APA

Meeusen, J. W., Yi, X., Cotten, S. W., Nielsen, J. B., Donato, L. J., Jones, P. M., Muthukumar, A. R., Zubirán, R., Remaley, A. T., & Cao, J. (2025). Modern Low-Density Lipoprotein Cholesterol Formulas Outperform Direct Methods in Patients with Hypertriglyceridemia and Low Levels of Low-Density Lipoprotein Cholesterol. Clinical Chemistry, 71(11), 1138-1146. https://doi.org/10.1093/clinchem/hvaf099

Vancouver

Meeusen JW, Yi X, Cotten SW, Nielsen JB, Donato LJ, Jones PM, et al. Modern Low-Density Lipoprotein Cholesterol Formulas Outperform Direct Methods in Patients with Hypertriglyceridemia and Low Levels of Low-Density Lipoprotein Cholesterol. Clinical Chemistry. 2025;71(11):1138-1146. doi:10.1093/clinchem/hvaf099

BibTeX
@article{Meeusen2025,
  author = {Meeusen, Jeffrey W and Yi, Xin and Cotten, Steven W and Nielsen, Jacob B and Donato, Leslie J and Jones, Patricia M and Muthukumar, Alagar R and Zubirán, Rafael and Remaley, Alan T and Cao, Jing},
  title = {Modern Low-Density Lipoprotein Cholesterol Formulas Outperform Direct Methods in Patients with Hypertriglyceridemia and Low Levels of Low-Density Lipoprotein Cholesterol},
  journal = {Clinical Chemistry},
  year = {2025},
  volume = {71},
  number = {11},
  pages = {1138--1146},
  doi = {10.1093/clinchem/hvaf099}
}
Kostenlos starten →